Rigetti Computing Inc (RGTI) Q4 2025 Earnings Call Transcript

Why It Matters

The results demonstrate Revvity’s resilience amid market headwinds and signal a strategic shift toward high‑margin AI software, enhancing long‑term shareholder value.

Key Takeaways

• Q4 revenue $772M, 4% organic growth.
• Diagnostics segment up 7% organic.
• Adjusted EPS $1.70, exceeds guidance.
• Share buybacks $1.5B since 2023.
• Launched Signals Synthetica AI platform with Lilly.

Pulse Analysis

Revvity’s fourth‑quarter performance underscores a rare blend of steady top‑line growth and disciplined capital allocation. Despite macro pressures—including tariff impacts, foreign‑exchange volatility, and shifting NIH funding—the company delivered a 4% organic revenue rise and a 7% surge in its diagnostics business, outpacing analyst expectations. Adjusted operating margin held near 30%, while free cash flow conversion exceeded 80%, providing the financial flexibility to repurchase $800 million of shares this year. Such buyback intensity, totaling $1.5 billion since the 2023 rebrand, reflects confidence in the firm’s long‑term earnings trajectory and supports earnings per share expansion.

The launch of Signals Synthetica marks Revvity’s decisive entry into AI‑driven drug discovery, positioning its platform as a central hub for pre‑clinical R&D. Partnering with Lilly’s Tune Lab initiative, the service embeds cutting‑edge machine‑learning models directly into scientists’ workflows, promising faster iteration cycles and reduced development timelines. In a market where biotech firms increasingly seek AI augmentation, Revvity’s deep integration with major pharma customers gives it a competitive moat, while the anticipated 40% ARR growth in its software segment signals robust demand for subscription‑based analytics.

Looking ahead, Revvity’s 2026 outlook blends modest organic growth expectations (2‑3%) with incremental revenue from the recent ACD acquisition and favorable FX tailwinds. Cost‑efficiency programs slated for completion by Q2 should lift adjusted operating margins to 28%, enhancing profitability. The guidance, coupled with a projected EPS range of $5.35‑$5.45, suggests high‑single‑digit earnings growth, reinforcing the company’s long‑range plan. Investors will likely view the combination of disciplined buybacks, expanding AI software revenue, and margin improvement as a compelling value proposition in the life‑sciences sector.